Here is the title of the phase 2 trial as seen on clinicaltrials.gov
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity
This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Shire
Information provided by (Responsible Party):
Part D of the phase 2 study with 120 subjects will be conducted at hospitals in Italy, Netherlands, Poland, Sweden and the United Kingdom and will be complete in March 2015. I'd say they had quite a bit of success in Parts A, B and C.
Shire was "gifted" iPlex rights for ROP for the token sum of $11M because they will bear the cost of new manufacturing. Having a commercial supply will make it available for the already FDA-approved indication of short stature in 2018, along with any other potential indications that INSM can trial alone or with partners.
Absolutely, and after Greenspam issued his "irrational exuberance" warning, the markets resumed their upward climb in less than two months, eventually more than doubling from the time of his warning. I am eyeing a head and shoulders pattern in INSM which points to a target of around $16, which is at the 50% retracement between the 4/2/14 high of $20.04 and the $11.90-$11.82 double bottom lows of 4/15 and 6/3. $16 would be a good price to start averaging in long calls and short puts if we even get there. I think Yellen's mention of biotechs means that pretty much ends her negative comments on them. Otherwise, it could be perceived as harassment. Don't expect any more negative comments aimed at biotechs from the Fed.
When did Alan Greenspan warn us about "irrational exuberance" in the markets? It was December 5, 1996. The S&P500 from that point continued upwards for nearly four more years, over doubling in the process before the dotcom bust. Don't hold your breath if you think a Fed warning will guarantee a correction any time soon.
Better get cracking and put some thumbs up on this tripe or you'll really start looking bad. You're slacking off. Get busy.
I'm glad to see he spends every spare moment thumbing up his own posts through various Yahoo accounts. Idle hands are the devil's workshop. As long as he stays busy in this pursuit, everyone can feel fairly safe that he won't wander off into some really destructive behavior.
It ain't a "drug'" It's an exact copy of the most potent growth hormone in the human body. Who do you think you're fooling? Who do you work for so diligently? You are failing in your mission because you are an idiot. Moron is a compliment for you.
IMO, rights for ROP were "gifted" to Shire for a mere $11M because now Shire will bear the cost of manufacturing and bringing a new supply of iPlex/Premiplex to market.
Talking up iPlex is like shoving a crucifix in a vampire's face, terry's face. It makes his blood boil. iPlex works for short stature and ROP and its associated complications and the vampire knows it is at the heart of regulation of cell division and growth. Why else would their be such a clamor for its ownership and control?
So right, blue. The strategic review (remember that?) produced a reverse merger with Transave and a shot at nearer term revenue with Arikayce. I hardly think that the brain trust behind Transave was merely interested in Insmed's $130M dollars at the time of te merger. They saw the possibilities of iPlex farther down the road when the settlement agreement expired.
They treat CF, INSM treats Pseudomonas infections. You think there will be no more Pseudomonas infections?
Well, the point I was trying to make was that new cases alone could support a $30 handle on a sustained basis. Obviously, a greater number of legacy cases will be treated during the first few years the drug is on the market. That was the first part of my post. $2.47 billion revenue for legacy cases might be spread over those first few years.
Here's a very conservative estimate based on published figures: 110,000 cases of NTM worldwide. In the US, 45% of cases were treated with drugs so you can assume that that percentage is seeking treatment and has access to insurance. So assume 49,500 worldwide would be treated. Use Lewis' most conservative treatment cost ($50,000) and you get $2.47 billion revenue. If you google "NTM cost of treatment" you will find several studies that show mean cost with existing drugs is around $5k ranging up to $36k. An approved, effective treatment should be able fetch a premium.
If the number of cases is growing at 10%, then that' s 11k /year. If 45% of those are treated, that's 4,950 new patients/yr x $50k = $247.5 million. Put a 6x multiplier on revenue and assume dilution of another 10M shares, then you get a share price of around $30, just from new cases. That's pretty darn close to the average analyst target price.
You never know what tidbits he may unleash in the presentation or in Q & A, sort of like the off-hand disclosure that several entities have made overtures to the company. Those tidbits are not in the official "Investor Presentation" but they are out there as public pronouncements. We shall see.
Au contraire. We are witnessing a pennant. Converging trendlines during a consolidation period following a huge breakout with diminishing volume. Look for a breakout above the descending top line of the pennant. Especially apparent on a 2 hr chart.